Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012

Size: px
Start display at page:

Download "Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012"

Transcription

1 Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict of interests No relevant financial relationships with any commercial companies pertaining to this educational activity 1

2 LTBI and TB Treatment Cara Christ, MD MS Chief Medical Officer, Division of Public Health Tuberculosis Control Officer Bureau Chief and Medical Director, Epidemiology and Disease Control Arizona Department of Health Services Objectives List 1 treatment option for LTBI Common and alternative regimens Monitoring for side effects and drug drug interactions New treatment options List 1 treatment option for TB disease Basic treatment for TB disease Management and monitoring during therapy 2

3 Antituberculosis Medications First line drugs Isoniazid Rifampin Rifapentine Rifabutin* Ethambutol Pyrazinamide * Not FDA approved for TB Second line drugs Cycloserine Ethionamide Levofloxacin* Moxifloxacin* PAS Streptomycin Amikacin/Kanamycin Capreomycin Antituberculosis Medications INH (Isoniazid) Majority of early bactericidal activity of multi drug TB regimens Excellent absorption and tissue penetration RIF (Rifampin) Bactericidal (highest sterilizing activity) Activity against rapidly dividing and semi dormant bacteria Cornerstone of short course therapy Well absorbed, good tissue levels 3

4 Antituberculosis Medications EMB (Ethambutol) Included in first line treatment to prevent emergence of RIF resistance PZA (Pyrazinamide) Bacteriostatic/sterilizing agent Greatest activity against dormant or semi dormant (slow growing) organisms within macrophages or caseous foci (acidic environment) Necessary for 6 month treatment Antituberculosis Medication Fluoroquinolones Preferred oral agents for treating drug resistant TB that is susceptible to this class of drugs, or for patients intolerant of first line drugs Activity against MTB: Moxifloxacin > levofloxacin > ofloxacin/ciprofloxacin Cross resistance 4

5 LTBI Treatment Why should you treat LTBI? Prevent progression of infection to disease Interrupt transmission of disease Evidence that this works? 1953: 52.6 cases/100,000 US Population 2010: 3.6 cases/100,000 US Population 5

6 Who should be treated for LTBI? A decision to test is a decision to treat! Tests should only be placed on persons who would benefit from treatment Occasional tests can be placed for administrative reasons These individuals should be evaluated on a case by case basis regarding initiation of treatment CDC Recommended LTBI Treatment How do you decide what to use? Efficacy, Duration, Cost Regimen Duration of therapy Cost INH (daily, 2x weekly DOT) 9 months (270 doses) $30* INH (daily, 2x weekly DOT) 6 months (180 doses) $20* Rifampin (600mg daily) 4 months (120 doses) $110 INH + RPT (once weekly DOT) 12 weeks (12 doses) $250* The longer the duration/more doses, the less likely your patient is to complete Rx! Fewer than 60% complete 9 months of INH! Medication costs *DOT cost not included 6

7 INH LTBI Therapy Regimen Duration of therapy Cost INH (daily, 2x weekly DOT) 9 months (270 doses) $30* INH (daily, 2x weekly DOT) 6 months (180 doses) $20* INH LTBI Therapy The standard treatment regimen for LTBI is nine months of daily INH. The regimen is very effective and is the preferred regimen for HIV infected people taking antiretroviral therapy, and children aged 2-11 years. CDC. November

8 Special Precautions While on INH Age 35 years and older Taking other medications on a long term basis Alcohol abuse History of incomplete INH treatment due to toxicity or adverse reactions Chronic liver disease Peripheral neuropathy Pregnancy INH Side Effects Hepatotoxicity Migraine Headaches Gastrointestinal Nausea, Diarrhea, Constipation Rash Peripheral Neuropathy Pyridoxine 50mg daily can prevent this 8

9 INH Hepatotoxicity Asymptomatic elevation of aminotransferases: 20% of patients Clinical hepatitis: 0.6% of patients Fulminant hepatitis (hepatic failure) Approximately 4/100,000 persons completing therapy (continued INH with symptoms of hepatitis, prior INH hepatotoxicity, malnutrition). INH Toxicity Monitoring The critical element for INH toxicity monitoring is CLINICAL MONITORING. Recommendations: Only prescribe 30 day supply at a time/no refills Emphasize to patients that INH treatment should be stopped immediately upon the earliest onset of symptoms Communicate with patient every 30 days Ask about Nausea, vomiting, Abdominal pain, Jaundice Document a note about this communication Only refill INH if the patient is OK Stop INH and/or check LFTs if not OK 9

10 Rifampin LTBI Therapy Regimen Duration of therapy Cost Rifampin (600mg daily) 4 months (120 doses) $110 Rifampin vs INH for Treatment of LTBI 4 month Rifampin regimen vs 9 months INH regimen Menzies et al AJRCCM 2004, 170; 445 Completion of therapy significantly better with rifampin with fewer side effects than INH Lardizabal et al Chest 2006, 130; 1712 Patients receiving rifampin were significantly more likely to complete therapy than those receiving INH Menzies et al Ann Int Med 2008, 149; 689 Significantly higher rate of treatment completion with fewer serious adverse events 10

11 Rifampin Treatment of LTBI Pros: Higher Completion Rates Less Side Effects Less Hepatotoxicty Cons: Drug Interactions Hormonal Contraceptives Warfarin Prednisone HIV Antiretrovirals Look up all drugs for interactions Orange Body Fluids Other Side Effects: Rash Thrombocytopenia Anemia Leukopenia Allergic Interstitial Nephritis INH/Rifapentine LTBI Treatment Regimen Duration of therapy Cost INH + RPT (once weekly DOT) 12 weeks (12 doses) $250* 11

12 INH/Rifapentine LTBI Therapy The 12 dose regimen of INH and RPT does not replace other recommended LTBI treatment regimens. Effective regimen option for otherwise healthy patients aged 12 years who have a predictive factor for greater likelihood of TB developing including: Recent TB contacts TST/IGRA Converters Radiographic findings of healed pulmonary TB CDC. November INH + RPT is NOT recommended for: Children under 2 yo HIV infected on Antiretroviral Therapy Drug interactions have not been established Presumed INH or Rifampin Resistance Pregnancy Safety in pregnancy has not been evaluated 12

13 Who should prescribe INH + RPT? Health Departments with established DOT programs Ideal candidates for the regimen are healthy LTBI patient discovered in contact investigation of active TB cases. If you choose to prescribe INH + RPT Emphasize to patients to seek medical attention upon the earliest onset of symptoms Baseline labs (LFTs) + monitoring for those at risk Elderly, certain conditions, risk of liver disease, abn. tests Monthly interview and physical examination Ask about Nausea, vomiting, Abdominal pain, Jaundice Look for drug hypersensitivity (hypotension, thrombocytopenia) Discontinue if LFTs >=5 times the upper limit Or >=3 times upper limit if patient is symptomatic CDC. November

14 If you choose to prescribe INH + RPT The regimen MUST be administered via DOT Be vigilant about Rifamycin drug interactions: Coumadin Hormonal contraception HIV Antiretrovirals Treatment of Active TB 14

15 Strategies Stressed in Guidelines Identification of patients at increased risk of relapse Obtain sputum smear and culture at end of initial phase of treatment (2months) Extended therapy (7 months) for patients with drugsusceptible pulmonary TB Who have cavitation on initial CXR and Who have a positive sputum culture at 2 months Counting Doses Define treatment completion by number of doses taken as well as duration of treatment Strategies Stressed in Guidelines RIFABUTIN (RBT): May be used as a primary drug for patients (especially HIV+) receiving medications having unacceptable interactions with rifampin (e.g. Protease Inhibitors, methadone) Fluoroquinolones (Levofloxacin or Moxifloxacin) may be used when first line drugs are not tolerated or the organism is resistant 15

16 Treatment of Culture Positive Drug Susceptible Pulmonary TB General conclusions from the literature 6 mo (26 wk) is the MINIMUM duration of RX 6 mo regimens require rifampin and INH throughout and PZA for the first 2 months 6 mo regimens are effective without INH if PZA given throughout Intermittent regimens (2 3x/wk): DOT ONLY Drug susceptible isolate Treatment of Culture Positive Drug Susceptible Pulmonary TB General conclusions from the literature: Without PZA minimum duration is 9 months Without rifampin minimum duration is 12 months (up to 18 months) Streptomycin and ethambutol (EMB) are approximately equivalent in effect Because of high incidence of Streptomycin resistance ethambutol is preferred for initial therapy Use streptomycin only if isolate is proven susceptible 16

17 Treatment Regimens for TB Disease Initiation phase of therapy 8 weeks INH, Rifampin and PZA +/ EMB Continuation phase of therapy (At least)18 weeks INH and Rifampin USPHS/IDSA Evidenced based Rating Scale Strength of the Recommendation A = Preferred B = Acceptable alternative C = Offer when unable to give A or B D = Should generally NOT be offered E = Should NEVER be offered Graded Quality of Supporting Evidence I = Randomized clinical trial II = Clinical trial, not randomized III = Expert opinion 17

18 Treatment of Culture Positive Pulmonary Tuberculosis Regimens Rated A I (HIV Uninfected) INITIAL PHASE 2 mo I,R,Z,E daily (56 doses, 8wks) or 2 mo I,R,Z,E 5x/wk (40 doses, 8wks) then CONTINUATION PHASE 4 mo I,R daily (126 doses, 18 wks) or 4 mo I,R 5x/wk (90 doses, 18 wks) or 4 mo I,R, 2x/wk (36 doses, 18 wks) Treatment of Culture Positive Pulmonary Tuberculosis Regimens Rated A II (HIV Uninfected) INITIAL PHASE 2weeks I,R,Z,E daily (14 doses) then 6 weeks I,R,Z,E twice weekly (12 doses) CONTINUATION PHASE (DOT only) 4mo I,R Twice weekly (36 doses, 18 weeks) 18

19 Treatment of Culture Positive Pulmonary Tuberculosis Regimens Rated B I (HIV Uninfected) Thrice weekly Hong Kong Regimen INITIAL PHASE 2mo I,R,Z,E 3x/week (24 doses, 8weeks) CONTINUATION PHASE 4mo I,R 3x/wk (54 doses, 18 weeks) Monthly clinical visit Case Management check response to therapy, evaluate for toxicity: hepatitis, visual acuity, Ishihara Plates repeat education (document) Monthly laboratory to check liver enzymes, CBC Pt educated regarding: signs/symptoms of visual and liver toxicity & the need to report these to provider Document susceptibility of isolate prior to stopping ethambutol For pulmonary TB Monthly sputum until two consecutive cultures are negative 2 month sputum is crucial 80% should convert by 2 months, 95% by 3 months 19

20 Drug Susceptibility Tests The Arizona State Laboratory will test for INH, Rifampin, and Ethambutol for each initial isolate and for requests processed by the State TB Program Isolates from a positive culture should be sent to the State Lab for DST Do not wait for culture to grow on solid media Prolongation of Continuation Phase Continuation phase increased to 7 months if initial CXR is cavitary & culture is positive at 2 months Rational for Extending Therapy Continuation of PZA for an additional 2 months was not helpful in drug susceptible disease Prolongation of continuation phase by 2 months decreased relapses in silico tuberculosis from 20% to 2% 20

21 Relapse Circumstance in which a patient becomes and remains culture negative while receiving antituberculosis drugs but at some point after completion of therapy, either becomes culture positive again or experiences clinical and radiographic deterioration consistent with active tuberculosis Confirm relapse bacteriologically Use DNA fingerprinting to identify new infection causing the disease versus relapse Identify drug susceptibility pattern of isolate Relapsed Tuberculosis Most relapses occur within the first 6 12 months after stopping therapy but some occur 5 or more years later Nearly all drug susceptible patients who were treated with a rifamycin and received DOT will relapse with drug susceptible organisms Treat with standard RIPE regimen 21

22 Relapsed Tuberculosis Management Strategies Suspect drug resistance if Patients treated with self administered therapy Patient was poorly adherent Patient deteriorates clinically or radiographically during initial weeks of treatment Consider expanded regimen, especially if immune suppressed RIPE plus a fluoroquinolone and an injectable Contact the ADHS Tuberculosis Program for assistance with further testing, if drug resistance is suspected Medical Factors Associated With Relapse Cavitary TB Extensive disease on CXR; bilateral infiltrates Positive 2 month culture Associated medical conditions Diabetes HIV Malabsorption of TB drugs Tuberculous lymphadenitis Underweight at diagnosis and failure to gain Drug resistant disease Prior treatment for tuberculosis 22

23 Factors Used to Prevent Relapse of Tuberculosis DOT Adherence Dosing intensity (Dose itself) Duration of therapy Intensive phase Continuation phase Both Rifampin containing regimen Importance of the Initiation Phase Evidence suggests Effect of dosing schedules on treatment efficacy is best harnessed in the initial phase Evidence has existed in vitro for several decades that: the more rapid the anti bacterial effect the less likely is the emergence of persisters and the lower is the risk of relapse. 23

24 Treatment in Special Situations TB With INH Resistance (2 studies) Dosing intermittency reduces TB treatment efficacy as shown by: Higher risk of treatment failure, relapse or acquired drug resistance Level of evidence 1+ Grade of evidence: A Avoid dosing intermittency, especially in the initial phase in the presence of INH resistance Chang; Thorax December,

25 Treatment of INH Resistant TB Duration of treatment and # drugs in regimen depend on patient s immune system and the extent of disease Normal host and minimal to moderate disease Rifampin, PZA, Ethambutol for 6 9 months Daily therapy preferred, no < three times weekly Impaired host or extensive, cavitary disease Add quinolone at least first 2 months Daily therapy Nine months Active TB During Pregnancy Diagnosis may be difficult Respiratory symptoms common in late pregnancy Reluctance to do a CXR Extra pulmonary disease is even more difficult Outcomes for BOTH mom and baby are improved with treatment during pregnancy Infection control is important at time of delivery if mom is still infectious 25

26 Treatment: Active TB During Pregnancy INH, Rifampin, Ethambutol x 9 months Stop ethambutol if susceptible to INH and rifampin PZA only if drug resistance is present PZA regarded as safe by most countries in world Follow carefully for hepatotoxicity risk is increased During pregnancy Three months postpartum Delayed Response Culture Positive at 3 Months Consider repeat susceptibility studies on last positive culture at 3 months Assess patient adherence Consider serum drug levels Evaluate response to therapy Clinically and radiographically 26

27 Treatment Failure Culture Positive at 4 Months Repeat susceptibility studies On last positive culture And request on a new sputum culture now Serum drug levels if not previously done Clinical evaluation Augment therapy Add at least two and preferably three new drugs to which the isolate is likely to be susceptible Even if no clinical or radiographic evidence of failure MMWR Treatment of Tuberculosis 2003; 52 Tuberculosis Drug Serum Level Monitoring Recommended Delayed response to therapy Advanced AIDS with evidence of malabsorption Seriously ill patient to maximize therapy Toxicity evaluation Use of second line drugs Acquired drug resistance Relapse Potential for drug drug interactions Renal and hepatic insufficiency 27

28 Culture Negative TB TB suspect with positive TST or IGRA Risk factors for TB Abnormal CXR Usually clinical symptoms All cultures are negative Classify based on clinical and/or radiograph response to treatment at 2 months Clinical or CXR improvement Culture Negative TB Treat for 4 months (children and HIV + 6 months) RIPE for 2 months, then RIE +/ PZA dependent on INH resistance Summary There are several acceptable regimens for treating LTBI and TB Careful monitoring of the patient during treatment is essential Follow treatment recommendations in MMWR Treatment of Tuberculosis 2003 Contact the State TB Program or Heartland with any treatment questions 28

29 Where to Get More Information Arizona Department of Health Services Tuberculosis Control Program Heartland National TB Center TEX LUNG: Medical Consultation and Technical Assistance Line Future training courses CDC Division of Tuberculosis Elimination TB Educate TBresources.com 29

TB Intensive San Antonio, Texas

TB Intensive San Antonio, Texas TB Intensive San Antonio, Texas April 6-8, 2011 TB Disease: ATS/CDC/IDSA Guidelines Barbara Seaworth, MD Thursday April 7, 2011 Barbara Seaworth, MD has the following disclosures to make: Has received

More information

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has

More information

Tuberculosis Intensive November 17 20, 2015 San Antonio, TX

Tuberculosis Intensive November 17 20, 2015 San Antonio, TX Treatment of Tuberculosis Elizabeth S. Guy, MD November 17, 2015 Tuberculosis Intensive November 17 20, 2015 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Elizabeth S. Guy, MD has the following disclosures

More information

Drug Interactions Lisa Armitige, MD, PhD November 17, 2010

Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant

More information

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017 Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has

More information

Treatment of Tuberculosis

Treatment of Tuberculosis TB Intensive Tyler, Texas June 1-3, 2009 Treatment of Tuberculosis Barbara Seaworth, MD June 3, 2009 Treatment of Tuberculosis Barbara J Seaworth MD Medical Director Heartland National TB Center 1 Purpose

More information

Treatment of Tuberculosis

Treatment of Tuberculosis Treatment of Tuberculosis Marcos Burgos, MD April 5, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures to make: No conflict

More information

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH Assistant Professor University of Texas Health Science Center Staff Physician, Texas Center for Infectious Diseases TB Nurse Case

More information

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either

More information

Diagnosis and Treatment of Tuberculosis, 2011

Diagnosis and Treatment of Tuberculosis, 2011 Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is

More information

has the following disclosures to make:

has the following disclosures to make: CLINICAL DIAGNOSIS AND MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH September 22, 2015 TB Nurse Case Management September 22 24, 2015 San Antonio. TX EXCELLENCE EXPERTISE INNOVATION Annie Kizilbash

More information

Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011

Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011 TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011 Lisa Armitige, MD, PhD has the following disclosures to make:

More information

Treatment of Tuberculosis

Treatment of Tuberculosis TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features

More information

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015 Diagnosis & Medical Case Management of TB Disease Lisa Armitige, MD, PhD October 22, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE

More information

Treatment of Active Tuberculosis

Treatment of Active Tuberculosis Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest

More information

TB in the Correctional Setting Florence, Arizona October 7, 2014

TB in the Correctional Setting Florence, Arizona October 7, 2014 TB in the Correctional Setting Florence, Arizona October 7, 2014 Diagnosis and Treatment of TB Disease Renuka Khurana, MBBS, MPH October 7, 2014 Renuka Khurana, MSSB, MPH has the following disclosures

More information

Treatment of Tuberculosis

Treatment of Tuberculosis Treatment of Tuberculosis, 1940 s Treatment of Tuberculosis ATS/CDC/IDSA Joint Statement 2003 Saskatchewan Lung Association Outline, 2012 Treatment of Tuberculosis Principles of treatment of tuberculosis

More information

Diagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015

Diagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015 Diagnosis and Medical Management of TB Disease Quratulian Annie Kizilbash, MD, MPH March 17, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION Quratulian

More information

LTBI Videos-Treatment

LTBI Videos-Treatment LTBI Videos-Treatment This program is presented by the Global Tuberculosis Institute and is based on recommendations from the Centers for Disease Control and Prevention. This is the third in a series of

More information

Marcos Burgos, MD has the following disclosures to make:

Marcos Burgos, MD has the following disclosures to make: Guidelines for the Treatment of Tuberculosis Marcos Burgos, MD May 13, 2015 TB for Pulmonologist March 13, 2015 Phoenix, AZ EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures

More information

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI: Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global

More information

TB Nurse Case Management San Antonio, Texas April 9-11, 2013

TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB / Dose Counting Rachel Munoz, RN. TB Nurse Case Manager/Nurse Consultant Austin/Travis County Health Department April 10, 2013 Rachel Munoz,

More information

Treatment of Latent TB Infection (LTBI)

Treatment of Latent TB Infection (LTBI) Treatment of Latent TB Infection (LTBI) Mahesh C. Patel, MD June 14, 2017 2014 MFMER slide-1 Mahesh C. Patel, MD Associate Professor Treatment of LTBI Department of Internal Medicine, Division of Infectious

More information

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014 Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014 Tuberculosis Pathogenesis and Treatment of Latent TB Infection Lisa Armitige, MD, PhD August 13, 2014 Lisa Armitige,

More information

CLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease

CLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease CLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease Barbara J Seaworth MD Medical Director Heartland National TB Center Professor of Medicine University of Texas Health Center Tyler Barbara J Seaworth MD has

More information

6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None

6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None TB TREATMENT Bijan Ghassemieh, MD Seattle TB Clinical Intensive 2018 Disclosures None 1 Objectives Understand the following Rationale and goals for standard TB regimen When to initiate TB treatment Standard

More information

Diagnosis and Medical Management of Latent TB Infection

Diagnosis and Medical Management of Latent TB Infection Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,

More information

Treatment: First Line Drugs TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS TREATMENT: GENERAL PRINCIPLES MECHANISM OF ACTION MID 27

Treatment: First Line Drugs TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS TREATMENT: GENERAL PRINCIPLES MECHANISM OF ACTION MID 27 TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS Treatment: First Line Drugs 1. ISONIAZID = INH Bacteriocidal against dividing organisms Dose = 300mg = one pill = well absorbed Good CNS penetration Can be

More information

Treatment of Tuberculosis, 2017

Treatment of Tuberculosis, 2017 Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,

More information

TB Intensive San Antonio, Texas May 7-10, 2013

TB Intensive San Antonio, Texas May 7-10, 2013 TB Intensive San Antonio, Texas May 7-10, 2013 TB in the HIV Patient Lisa Armitige, MD, PhD May 09, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant

More information

Treatment of Tuberculosis

Treatment of Tuberculosis Treatment of Tuberculosis American Thoracic Society, CDC, and Infectious Diseases Society of America Please note: An erratum has been published for this article. To view the erratum, please click here.

More information

Case Management of the TB/HIV Infected Patient

Case Management of the TB/HIV Infected Patient TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Case Management of the TB/HIV Infected Patient Sarah Hoffman, MPH, MSN, ACRN December 9, 2009 TB/HIV: Considerations in the Care of the Coinfected

More information

Managing the Patients Response to TB Treatment

Managing the Patients Response to TB Treatment Managing the Patients Response to TB Treatment Barbarah Martinez, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Barbarah Martinez, RN, BSN has

More information

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012 TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release

More information

LTBI in Special Populations John Nava, MD October 5, 2010

LTBI in Special Populations John Nava, MD October 5, 2010 Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 LTBI in Special Populations John Nava, MD October 5, 2010 2 Treatment of Latent TB Infection in Special Populations John

More information

Treatment of TB. David Griffith, MD May 12, TB for Community Providers. Phoenix, Arizona

Treatment of TB. David Griffith, MD May 12, TB for Community Providers. Phoenix, Arizona Treatment of TB David Griffith, MD May 12, 2015 TB for Community Providers May 12, 2015 Phoenix, Arizona EXCELLENCE EXPERTISE INNOVATION David Griffith, MD has the following disclosures to make: No conflict

More information

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures

More information

Pediatric TB Intensive San Antonio, Texas October 14, 2013

Pediatric TB Intensive San Antonio, Texas October 14, 2013 Pediatric TB Intensive San Antonio, Texas October 14, 2013 Treatment of Tuberculosis in Children Jeffrey R. Starke, M.D. Professor of Pediatrics October 14, 2013 Jeffrey R. Starke, M.D. has the following

More information

Standard TB Treatment

Standard TB Treatment Standard TB Treatment Chris Keh, MD TB Controller, TB Prevention and Control Program, San Francisco Department of Public Health Assistant Clinical Professor, Division of Infectious Diseases, University

More information

TB Nurse Case Management San Antonio, Texas March 7 9, Clinical Diagnosis and

TB Nurse Case Management San Antonio, Texas March 7 9, Clinical Diagnosis and TB Nurse Case Management San Antonio, Texas March 7 9, 2012 Clinical Diagnosis and Management of LTBI Lynn Horvath, MD March 7, 2012 Lynn Horvath, MD has the following disclosures to make: No conflict

More information

Anti Tuberculosis Medications: Side Effects & adverse Events

Anti Tuberculosis Medications: Side Effects & adverse Events Anti Tuberculosis Medications: Side Effects & adverse Events Diana Fortune, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Diana Fortune, RN,

More information

TB Intensive San Antonio, Texas. TB/HIV Co-Infection. Lisa Armitige, MD, PhD has the following disclosures to make:

TB Intensive San Antonio, Texas. TB/HIV Co-Infection. Lisa Armitige, MD, PhD has the following disclosures to make: TB Intensive San Antonio, Texas August 2-5, 2011 TB/HIV Co-Infection Lisa Armitige, MD, PhD August 4, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant

More information

Latent TB Infection Treatment

Latent TB Infection Treatment Latent TB Infection Treatment Douglas B. Hornick, MD Pulmonologist w/ Infectious Attitude Division of Pulmonary/Critical Care/Occ Med UI Carver College of Medicine 2014 MFMER slide-1 Disclosures: None

More information

Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015

Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015 Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015 Initiation Phase Part 1 Ginny Dowell, RN, BSN February 4, 2015 Ginny Dowell RN, BSN has the following disclosures to make:

More information

Treatment of Tuberculosis

Treatment of Tuberculosis Recommendations and Reports June 20, 2003 / 52(RR11);1-77 Recommendations and Reports June 20, 2003 / 52(RR11);1-77 Treatment of Tuberculosis American Thoracic Society, CDC, and Infectious Diseases Society

More information

TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION

TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION Michelle Haas, M.D. Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES No relevant financial relationships OBJECTIVES

More information

Managing Complex TB Cases Diana M. Nilsen, MD, RN

Managing Complex TB Cases Diana M. Nilsen, MD, RN Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private

More information

Chapter 5 Treatment for Latent Tuberculosis Infection

Chapter 5 Treatment for Latent Tuberculosis Infection Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI

More information

Tuberculosis Intensive

Tuberculosis Intensive Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 TB in the HIV Patient Lisa Armitige, MD, PhD April 6, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests

More information

Medication Administration and Adverse Reactions Alisha Blair, LVN September 28, 2011

Medication Administration and Adverse Reactions Alisha Blair, LVN September 28, 2011 TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Medication Administration and Adverse Reactions Alisha Blair, LVN September 28, 2011 Alisha Blair, LVN, has the following disclosures to make:

More information

HEALTH SERVICES POLICY & PROCEDURE MANUAL

HEALTH SERVICES POLICY & PROCEDURE MANUAL PAGE 1 of 7 References Related ACA Standards 4 th Edition Standards for Adult Correctional Institutions 4-4350, 4-4355 These guidelines are based on the recommendations of the American Thoracic Society

More information

TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012

TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012 TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012 Challenges of TB Treatment in Special Populations in Corrections Marcos Burgos, MD November 28, 2012 Marcos Burgos, MD has the following

More information

TB in Corrections Phoenix, Arizona

TB in Corrections Phoenix, Arizona TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests

More information

TB Intensive San Antonio, Texas November 11 14, 2014

TB Intensive San Antonio, Texas November 11 14, 2014 TB Intensive San Antonio, Texas November 11 14, 2014 Tuberculosis Pathogenesis and Treatment of Latent TB Infection Lynn Horvath, MD November 11, 2014 Lynn Horvath, MD has the following disclosures to

More information

TB and Comorbidities Adriana Vasquez, MD April 12, 2018

TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB Nurse Case Management April 10 12, 2018 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Adriana Vasquez, MD has the following disclosures to make:

More information

Debbie Onofre, RN, BSN March 18, TB Nurse Case Management March 17 19, 2015 San Antonio, Texas

Debbie Onofre, RN, BSN March 18, TB Nurse Case Management March 17 19, 2015 San Antonio, Texas Managing and Monitoring Side Effects and Toxicities of Anti TB Therapy Debbie Onofre, RN, BSN March 18, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION

More information

Disclosures. Outline. No disclosures or conflicts of interest to report. Special LTBI situations. H t it d id ff t

Disclosures. Outline. No disclosures or conflicts of interest to report. Special LTBI situations. H t it d id ff t Selected Topics in LTBI June 2, 2015 Bijan Ghassemieh, MD Senior Fellow UW Division of Pulmonary/Critical Care Disclosures No disclosures or conflicts of interest to report Outline Special LTBI situations

More information

Contact Investigation and Prevention in the USA

Contact Investigation and Prevention in the USA Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis

More information

TB in the Patient with HIV

TB in the Patient with HIV TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to

More information

TB Grand Rounds. Reynard McDonald, MD & Henry Fraimow, MD January 30, Outline

TB Grand Rounds. Reynard McDonald, MD & Henry Fraimow, MD January 30, Outline TB Grand Rounds Reynard McDonald, MD & Henry Fraimow, MD January 30, 2007 Outline Overview of 2006 ATS statement regarding hepatotoxicity of anti-tb therapy Case examples highlighting management of patients

More information

Treatment and Monitoring

Treatment and Monitoring Treatment and Monitoring Disclosures We have no actual or potential conflicts of interest in relation to this presentations. We have no financial relationships to disclose. Learning Objectives After this

More information

Official ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (Nahid et al, CID 2016)

Official ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (Nahid et al, CID 2016) Official ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (Nahid et al, CID 2016) APPENDIX C: DRUGS IN CURRENT USE The U.S. Food and Drug Administration (FDA) has approved

More information

TB Intensive Houston, Texas October 15-17, 2013

TB Intensive Houston, Texas October 15-17, 2013 TB Intensive Houston, Texas October 15-17, 2013 Tuberculosis Pathogenesis and Treatment f Latent TB Infection Lynn Horvath, MD October 15, 2013 Lynn Horvath, MD has the following disclosures to make: No

More information

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.

More information

At the end of this session, participants will be able to:

At the end of this session, participants will be able to: Advanced Concepts in Pediatric TB: Treatment of Tuberculosis Disease Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [with help from Andrea Cruz, M.D.] Objectives At the end

More information

Antimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018

Antimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018 Antimycobacterial drugs Dr.Naza M.Ali lec 14-15 6 Dec 2018 About one-third of the world s population is infected with M. tuberculosis With 30 million people having active disease. Worldwide, 9 million

More information

Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016

Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016 Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016 TB Nurse Case Management September 7-9, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Jessica Quintero, M.Ed., has the following disclosures

More information

TB Nurse Case Management

TB Nurse Case Management TB Nurse Case Management San Antonio, Texas March 2-4, 2011 TB Medications and Adverse Effects Debbie Onofre, RN, BSN March 3, 2011 Debbie Onofre, RN, BSN has the following disclosures to make: No conflict

More information

Tuberculosis: A Provider s Guide to

Tuberculosis: A Provider s Guide to Tuberculosis: A Provider s Guide to Diagnosis and Treatment of Active Tuberculosis (TB) Disease and Screening and Treatment of Latent Tuberculosis Infection (LTBI) Alameda County Health Care Services Agency

More information

Treatment of Tuberculosis Disease. Treatment of Tuberculosis. Decision to Treat Initiation of Therapy 1

Treatment of Tuberculosis Disease. Treatment of Tuberculosis. Decision to Treat Initiation of Therapy 1 Treatment of Tuberculosis Some Highlights of Most Recent Update Treatment of Tuberculosis Disease Germaine Jacquette, MD Physician Specialist NJMS Global Tuberculosis Institute September 15, 2010 The provider

More information

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection? Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:

More information

Fundamentals of Tuberculosis (TB)

Fundamentals of Tuberculosis (TB) TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported

More information

Contact Investigation

Contact Investigation Tuberculosis Ann Raftery, RN, PHN, MSc GHS Learning Objectives Upon completion of this session, participants will be able to: Describe the criteria used and method for determining the infectious period

More information

TB Nurse Case Management San Antonio, TX. TB Medications and Adverse Effects

TB Nurse Case Management San Antonio, TX. TB Medications and Adverse Effects TB Nurse Case Management San Antonio, TX April 1 3, 2014 TB Medications and Adverse Effects Debbie Onofre RN, BSN Nurse Consultant/ Nurse Educator Heartland National TB Center April 1, 2014 Debbie Onofre,

More information

Patient History 1. Patient History 2. Social History. The Role of Surgery in the Management of TB. Reynard McDonald, MD & Paul Bolanowski, MD

Patient History 1. Patient History 2. Social History. The Role of Surgery in the Management of TB. Reynard McDonald, MD & Paul Bolanowski, MD Patient History 1 The Role of Surgery in the Management of TB Reynard McDonald, MD & Paul Bolanowski, MD September 16, 2010 42 y/o AA male was initially diagnosed with pansensitive pulmonary TB in 1986

More information

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Managing Anti-TB Therapy Side Effects and Complications Lisa Armitige, MD, PhD May 9, 2012 Lisa Armitige, MD, PhD has the following

More information

Tuberculosis Tools: A Clinical Update

Tuberculosis Tools: A Clinical Update Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary

More information

Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013

Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013 Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013 1 TB in Toronto - risk groups Diagnosis of active TB LTBI diagnosis and management Infection control 2 TB in Toronto Case

More information

TB Update: March 2012

TB Update: March 2012 TB Update: March 2012 David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Public Health 1 TB Update: March 2012 IGRAs vs TST LTBI A New Regimen NAATs What is Their

More information

SA TB Guidelines The interface with Advanced Clinical Care

SA TB Guidelines The interface with Advanced Clinical Care SA TB Guidelines The interface with Advanced Clinical Care Dr Kogie Naidoo (MBCHB, PHD) Head: CAPRISA Treatment Research Programme Honorary Lecturer - UKZN Department of Public Heath Medicine Annual Workshop

More information

TB in Corrections Phoenix, Arizona

TB in Corrections Phoenix, Arizona TB in Corrections Phoenix, Arizona March 24, 2011 Contact Investigation in the Correctional Setting Jessica Quintero, BAAS March 24, 2011 Jessica Quintero, BAAS has the following disclosures to make: No

More information

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014 What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks

More information

Advanced Concepts in Pediatric Tuberculosis

Advanced Concepts in Pediatric Tuberculosis Advanced Concepts in Pediatric Tuberculosis: Nizar F. Maraqa, MD, FPIDS Division of Pediatric Infectious Diseases & Immunology University of Florida College of Medicine - Jacksonville Advanced Concepts

More information

Management of Patients with TB Infection Catalina Navarro, RN, BSN April 7, 2015

Management of Patients with TB Infection Catalina Navarro, RN, BSN April 7, 2015 Management of Patients with TB Infection Catalina Navarro, RN, BSN April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Catalina Navarro,

More information

Latent TB, TB and the Role of the Health Department

Latent TB, TB and the Role of the Health Department Latent TB, TB and the Role of the Health Department Elaine Darnall, RN, BSN, CIC TB Nurse Consultant Illinois Dept of Public Health March 21, 2018 Elaine Darnall has disclosed that there is no actual or

More information

Tuberculosis: Where Are We Now?

Tuberculosis: Where Are We Now? Tuberculosis: Where Are We Now? Amee Patrawalla MD MPH Rutgers - NJ Medical School Global TB Institute Rutgers, The State University of New Jersey Learning Objectives Understand the current epidemiologic

More information

Let s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Let s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Abstract Nearly 50% of patients with

More information

Tuberculosis Update. Objectives. Introduction. Tuberculosis Update Eric J. Bihler, DO

Tuberculosis Update. Objectives. Introduction. Tuberculosis Update Eric J. Bihler, DO Tuberculosis Update Eric Bihler Objectives Brief overview of epidemiology and transmission Differentiate between latent and active tuberculosis Treatment of tuberculosis Common side effects of therapy

More information

TB Nurse Assessment. Ginny Dowell, RN, BSN October 21, 2015

TB Nurse Assessment. Ginny Dowell, RN, BSN October 21, 2015 TB Nurse Assessment Ginny Dowell, RN, BSN October 21, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19-22, 2015 Wichita, KS EXCELLENCE EXPERTISE INNOVATION Ginny Dowell,

More information

TB BASICS: PRIORITIES AND CLASSIFICATIONS

TB BASICS: PRIORITIES AND CLASSIFICATIONS TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE NOVEMBER 1-4, 2016 TB BASICS: PRIORITIES AND CLASSIFICATIONS LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1.

More information

Pediatric Tuberculosis: The Essentials October 8, 2014

Pediatric Tuberculosis: The Essentials October 8, 2014 Pediatric Tuberculosis: The Essentials Ann M Loeffler, MD Randall Children s Hospital at Legacy Emanuel Portland, Oregon Curry International TB Center Disclosures Nothing to disclose Learning Objectives

More information

Drug Side Effects and Toxicity

Drug Side Effects and Toxicity Drug Side Effects and Toxicity Gwen A. Huitt, MD MS Professor, Division of Mycobacterial and Respiratory Infections National Jewish Health Disclosures None Toxicity Nausea and vomiting Any Drug Can Cause

More information

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014 Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014 TB Drugs David Griffith, MD August 13, 2014 David Griffith, MD has the following disclosures to make: No conflict

More information

Dosage and Administration

Dosage and Administration SIRTURO product information for healthcare providers 2 WARNINGS: An increased risk of death was seen in the SIRTURO (bedaquiline) treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81,

More information

Tuberculosis: update 2013

Tuberculosis: update 2013 Tuberculosis: update 2013 William R. Bishai, MD, PhD Center for TB Research Division of Infectious Diseases Department of Medicine Johns Hopkins School of Medicine Question 1 A TB speaker at a major conference

More information

TREATMENT OF LATENT TB INFECTION (LTBI)...

TREATMENT OF LATENT TB INFECTION (LTBI)... July, 2018 Page 1 TABLE OF CONTENTS 6.0 TREATMENT OF LATENT TB INFECTION (LTBI)... 2 6.1 Overview... 2 6.2 Procedure for Initiation of LTBI Treatment... 4 6.3 Recommended LTBI Treatment Regimens... 5 6.4

More information

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines:

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis OBJECTIVES

More information

Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None

Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None Disclosures Updates in TB for the PCP: Opportunities for Prevention None Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology, California TB Control Branch Assistant Clinical Professor, Division

More information